First Patient Dosed in Ph 1 Trial of KST-6051 in Patients with KRAS-driven Malignancies
“This strategic agreement represents a major validation of our lead pan-KRAS program,” said Dr. Frank Haluska, Chief Executive Officer of Kestrel Therapeutics. “AbbVie’s commitment underscores the potential of our approach to address one of the most important targets in oncology. And dosing the first patient in our Phase 1 trial marks an important step forward in the clinical development of KST-6051. We believe KST-6051 has the potential to address significant unmet medical needs in patients with KRASdriven cancers and look forward to advancing this study and generating initial clinical data with AbbVie.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).